publication date: May. 19, 2017

Funding Opportunities SU2C, Genentech announce second “catalyst” collaboration

Stand Up To Cancer announced a second SU2C Catalyst collaboration with Genentech, a member of the Roche Group, aimed at accelerating the development of new cancer treatments and combination therapies through clinical trials using Genentech medicines, including both commercial and pre-commercial treatments.

The American Association for Cancer Research, SU2C’s Scientific Partner, issued a Request for Proposals to the scientific community, with responses due June 27.

The collaboration with Genentech is expected to fund one or more proposals, each in the range of $1 million to $3 million. Clinical trials must be at the heart of each proposal. Genentech also collaborated in an initial round of SU2C Catalyst projects launched last year.

Proposals for SU2C Catalyst Research Grant: Genentech-Supported projects must be submitted by noon U.S. Eastern Time on June 27. Program guidelines can be found at http://www.aacr.org/genentech. Proposals must be submitted through the proposalCentral website at https://proposalcentral.altum.com.

SU2C Catalyst is a collaborative program managed for SU2C by AACR that is intended to leverage all facets of the pharmaceutical, biotechnology, diagnostic, and devices industries to bring new treatments to patients as rapidly as possible through early-phase clinical trials or translational research.

The Genentech-supported projects will support clinical trials focusing on new … Continue reading SU2C, Genentech announce second “catalyst” collaboration

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.